Relative Intelligence · Medical Diagnostics

How Natera (NTRA) compares with the whole market and its popular alternatives
Built by QuantCommons' quantitative engine, this page is about relative opportunity, not data on NTRA alone. It places NTRA (Natera, Inc.) against 17 popular alternatives, its neighboring categories and the entire market of over 10,000 U.S.-listed stocks and ETFs, and surfaces what has done better on consistent outperformance, return for the risk taken, behavior in real market crashes and diversification. The result is a clearer view of where NTRA stands in the market, and of the alternatives worth a closer look.
Period covered: NTRA's full trading record, from July 2015 through September 2026. The crash tests reach back to 2000 using older funds and the S&P 500. All returns include reinvested dividends. Data as of October 20, 2026.
Data as of October 20, 2026. Full tables and charts read best on a larger screen.
On this page12 sections
Key findings
- Right nowOver the past 6 months, NTRA rose 95.4% against 9.1% for the S&P 500 and 11.2% for the Nasdaq 100. Its medical diagnostic peers were far apart over the past 6 months, from CDNA (CareDx, up 225%) to LH (Labcorp, up 20.6%). Consistency ↓
- Stock or market?NTRA's 54.6% gain over the past 3 months far outran its industry: the medical diagnostics ETF IDNA (iShares Genomics Immunology and Healthcare ETF) rose 32.0%. The S&P 500 rose 3.9%. Last month cut against the tape: NTRA rose 9.5% while the S&P 500 fell 0.6%.
- Past 1 to 3 yearsNTRA has run far ahead of the market, rising 115% over the past year against 15.8% for the S&P 500 and 17.9% for the Nasdaq 100. The same gap shows up over 3 years (896% against 89.3%). The last two calendar years both went the same way: NTRA rose 44.7% in 2025, against 15.8% for the S&P 500 and 17.9% for the Nasdaq 100. By year ↓
- Long termNTRA turned $10,000 into $394,000 over the past decade, against $42,100 in the S&P 500. NTRA's 10-year return of 3,841% puts it ahead of 99% of the stocks worth at least $300 million with that much history. The S&P 500 returned 321%. Growth of $10,000 ↓
- In a crashAcross four sell-offs, NTRA has typically fallen 3.0 times as far as the S&P 500. Crash tests ↓
- DiversificationOver 10 years, NTRA's beta versus the S&P 500 was 1.40: in the S&P 500's rising months it gained 1.7 times as much as the index, and in falling months it lost 82% as much. NTRA is some diversification, but not a hedge: a correlation of 0.42 with the S&P 500 over 5 years and 0.44 with the total US market, more closely than 57% of stocks worth at least $300 million. Market capture ↓
- Better optionsAcross the whole market, NTRA outpaced 99% of stocks worth at least $300 million over the past decade. Even so, across the whole market, 125 of the 3,633 stocks and funds worth at least $500 million earned more than NTRA with less volatility over the past 5 years, among them NVDA (NVIDIA), TSM (Taiwan Semiconductor Manufacturing) and AVGO (Broadcom). Better options ↓
How much would $10,000 in NTRA have grown?
This chart tracks a hypothetical $10,000 investment in NTRA over the past 11 years, with dividends reinvested, alongside the same amount in the S&P 500, investments that ended ahead of NTRA over the same span and NTRA's popular alternatives, among those that traded for the entire period. A second view covers the past 5 years, the period the better options further down the page are judged on. It shows not only where each investment ended up but also how smooth or uneven the path was.
Note: NTRA began trading on July 1, 2015, so the chart cannot reach back to the dot-com bust, the 2008 financial crisis or two other sell-offs. It covers the most recent 11 years of NTRA's record, starting at the end of September 2015.
- $10,000 invested in NTRA at the end of September 2015 would have grown to $380,944 by September 2026, more than the $47,605 it would have become in SPY, an S&P 500 fund.
- Five of the eight other investments on the chart ended ahead of NTRA, and NVDA finished highest, at $3,837,604.
Choose a period
From the end of September 2015 to the end of September 2026. The scale is logarithmic, so equal steps up the chart are equal percentage gains. Hover over a fund in the key to pick out its line. 24 of the 2,591 stocks and funds worth at least $500 million that traded the whole period ended ahead of NTRA; the chart shows 5, closest alternatives first. The other 3 lines are popular alternatives, shown for context.
- NVDA$4M+38,276% total · +71.8% a year
- AMD$4M+35,467% total · +70.6% a year
- STRL$1M+11,865% total · +54.5% a year
- MU$728,938+7,189% total · +47.7% a year
- FIX$650,440+6,404% total · +46.2% a year
- NTRA$380,944+3,709% total · +39.2% a year
- CDNA$155,884+1,459% total · +28.4% a year
- SPY (S&P 500)$47,605+376% total · +15.2% a year
- NEO$32,268+223% total · +11.2% a year
- ILMN$16,017+60.2% total · +4.4% a year
From the end of September 2021 to the end of September 2026. The scale is logarithmic, so equal steps up the chart are equal percentage gains. Hover over a fund in the key to pick out its line. 232 of the 3,628 stocks and funds worth at least $500 million that traded the whole period ended ahead of NTRA; the chart shows 5, closest alternatives first. The other 3 lines are popular alternatives, shown for context.
- FIX$236,701+2,267% total · +88.3% a year
- STRL$216,918+2,069% total · +85.0% a year
- MU$153,675+1,437% total · +72.7% a year
- PBR-A$67,821+578% total · +46.6% a year
- SMH$48,982+390% total · +37.4% a year
- NTRA$37,089+271% total · +30.0% a year
- SPY (S&P 500)$19,000+90.0% total · +13.7% a year
- CDNA$10,257+2.6% total · +0.5% a year
- PSNL$8,462−15.4% total · −3.3% a year
- ILMN$6,943−30.6% total · −7.0% a year
NTRA at a glance
This section summarizes the key facts about the stock, its returns over periods from one to ten years and the risk it has carried, with dividends reinvested throughout. These figures serve as the baseline for every comparison that follows.
Note: NTRA began trading on July 1, 2015, so every figure here, including its worst decline, covers only the time since then. None of them reflect the dot-com bust, the 2008 financial crisis or two other sell-offs.
- NTRA's deepest decline since it began trading in 2015 was 77.7%, from September 2021 to May 2022. It took 28 months from the low to climb back to its old high.
- Over ten full calendar years, NTRA's best was 2020, when it returned 195%, and its worst was 2022, when it lost 57.0%. It lost money in three of those years.
- NTRA is 4.6% below its all-time high.
The company
- Market value
- $59B
- Industry
- Medical - Diagnostics & Research
- Price history from
- July 2015
Returns
- Past 1 year
- +115%total return
- Past 3 years
- +896%+115% a year
- Past 5 years
- +261%+29.3% a year
- Past 10 years
- +3,841%+44.4% a year
- Best calendar year
- +195%2020
- Worst calendar year
- −57.0%2022
- Losing years
- 3 of 10full calendar years
Risk
- Volatility
- 57.6%typical yearly swing, 5 years
- Sharpe ratio
- 0.74return per unit of risk, 5 years
- Worst decline ever
- −77.7%Sep 2021 to May 2022
- From its all-time high
- −4.6%below the peak
NTRA against the whole market
Where NTRA ranks among every stock and fund, and what across the market has done better.
How does NTRA rank among all stocks?
This section ranks NTRA on return, volatility, risk-adjusted return and worst decline against every stock worth at least $300 million with enough history. Where the comparisons with its popular alternatives show how NTRA stacks up against its peers, these rankings show where it stands in the market as a whole.
- NTRA's 10-year return ranks in the top 1% of the 2,202 stocks worth at least $300 million with 10 years of history.
- NTRA is among the more volatile stocks: its price swings rank in the bottom 24% of the 2,893 stocks worth at least $300 million, where the top is the calmest.
Ranked against U.S.-listed stocks worth at least $300M that have enough history for each measure, so the count changes from row to row; smaller stocks are left out. Lower volatility and smaller declines rank higher.
| Measure | NTRA | Rank | Standing |
|---|---|---|---|
| 1-year return | +115% | 135 of 3,287 | top 4% |
| 3-year return | +896% | 34 of 3,017 | top 1% |
| 5-year return | +261% | 213 of 2,893 | top 7% |
| 10-year return | +3,841% | 12 of 2,202 | top 1% |
| Volatility, 5 years | 57.6% | 2,206 of 2,893 | bottom 25% |
| Sharpe ratio, 5 years | 0.74 | 388 of 2,893 | top 13% |
| Worst decline, past 10 years | −77.7% | 1,554 of 2,187 | bottom 30% |
What has beaten NTRA on both return and risk?
Each dot is an investment, placed by how much it earned a year over the past 5 years (higher is better) and how much its price swung, its volatility (further left is calmer). NTRA sits where the dashed lines cross. Anything in the green box above and to the left earned more than NTRA with smaller swings, a better trade-off over this period on both counts. Past results are no promise, but a name in the box is worth a closer look.
- 124 stocks and one ETF worth at least $500 million sit in the green region: each earned more than NTRA over the past 5 years with smaller price swings. That is 3% of the 3,633 screened.
- Among those with at least half NTRA's swings, FIX has the best return for its risk: 77.0% a year at 46.7% volatility, 19% less than NTRA's 57.6%, and a Sharpe ratio (return above cash per unit of volatility) of 1.46 against 0.74 for NTRA. BELFB earned the most, 78.0% a year, while still swinging less than NTRA (52.1% against 57.6%).
Annual return is the annualized total return with dividends reinvested, and volatility the annualized swing in daily prices, both over 5 years. Labeled dots are the strongest picks from the table below and the names called out above, colored by how close they sit to NTRA; faint dots are 96 more of the 125 in the green region (the strongest, one per fund family). 3,633 stocks and funds worth at least $500 million were screened. Hover over a dot for its figures.
- The whole market
- Others in the green region
Is there a better investment than NTRA?
Investments that beat NTRA over the past 5 years on return, volatility, drawdowns, consistency, crash losses or fees, from its popular alternatives out to the whole market.
- Across the whole market, 125 of the 3,633 stocks and funds worth at least $500 million earned more than NTRA with less volatility over the past 5 years, among them NVDA, TSM and AVGO.
How this works
The table below lists investments that beat NTRA over the past 5 years on at least one of these measures: a higher annual return with lower volatility, a higher annual return at similar volatility, a similar return with lower volatility, a higher Sharpe ratio with a smaller worst decline, a higher total return in most periods from 3 months to 10 years, or smaller losses in recent market crashes. It checks NTRA's popular alternatives first, then the rest of its own and neighboring categories, then every stock and fund worth at least $500 million, and shows the strongest few in each group. The full list of those with a higher return and lower volatility than NTRA follows the table.
Annual return is the annualized total return with dividends reinvested. Annual return, volatility and the Sharpe ratio cover 5 years; the worst decline covers the past 10 years. Green marks a better figure than NTRA's. "On the frontier" means no other option shown or tested earned more with less volatility. Funds that hold the same thing are shown once. Beyond the popular alternatives, nothing with more than 1.5× NTRA's volatility counts as better.
These figures cover the past 5 years. Green marks a better figure than NTRA's.
| Investment | Why it is better | Past 5 years | Downside | Long run | Fit | ||||
|---|---|---|---|---|---|---|---|---|---|
| Annual return?higher is better | Volatility?lower is calmer | Sharpe?return per unit of risk | Worst decline?past 10 years | 10Y returntotal | Corr. with NTRA?lower diversifies more | Expenseper year | |||
| +29.3% | 57.6% | 0.74 | −77.7% | +3,841% | 1.00 | — | |||
| +12.7% | 17.1% | 0.79 | −33.7% | +321% | 0.42 | 0.09% | |||
| The whole marketbest 8 shownEvery other stock and fund worth at least $500 million. 183 of 3,580 passed at least one test. | |||||||||
| Higher return, similar volatilityHigher Sharpe, smaller worst declineHigher return in most periodsSmaller losses in recent crashes | +68.1% | 57.1% | 1.20 | −57.6% | +5,243% | 0.25 | — | ||
| On the frontierHigher return, lower volatilityHigher Sharpe, smaller worst declineSmaller losses in recent crashes | +77.0% | 46.7% | 1.46 | −49.7% | +5,305% | 0.33 | — | ||
| On the frontierHigher return, lower volatilityHigher Sharpe, smaller worst decline | +51.8% | 37.5% | 1.31 | −71.7% | +768% | -0.02 | — | ||
| Higher return, lower volatilityHigher Sharpe, smaller worst decline | +33.4% | 36.9% | 0.97 | −45.3% | +1,665% | 0.33 | 0.35% | ||
STRLSterling Infrastructure, Inc. · Engineering & Construction | Higher return, similar volatilityHigher Sharpe, smaller worst declineSmaller losses in recent crashes | +78.4% | 60.0% | 1.26 | −59.6% | +5,213% | 0.26 | — | |
| Higher return, similar volatilitySmaller losses in recent crashes | +35.7% | 57.6% | 0.82 | −65.5% | +7,583% | 0.27 | — | ||
| Similar return, lower volatilityHigher Sharpe, smaller worst decline | +29.5% | 38.4% | 0.87 | −54.2% | +352% | -0.04 | — | ||
SOXQInvesco PHLX Semiconductor ETF · Technology | Similar return, lower volatilityHigher Sharpe, smaller worst decline | +28.3% | 38.9% | 0.84 | −46.0% | — | 0.32 | 0.19% | |
What these numbers mean for NTRA
- Annual return
- NTRA returned 29.3% a year over the past 5 years with dividends reinvested, against 12.7% a year for the S&P 500. At that pace, $10,000 became about $36,100. Annual return is the steady yearly rate that would produce the same total result, so investments held over the same span compare fairly. Guide: What is performance and return? →
- Volatility
- NTRA's volatility over the past 5 years was 57.6%, 3.4 times the S&P 500's 17.1%. Volatility measures how widely returns swing around their average: in roughly two years out of three, NTRA's return lands within 57.6% of its average, either way. The higher it is, the rougher the ride and the harder it is to hold through a slump. Guide: Understanding and measuring risk (volatility) →
- Sharpe ratio
- NTRA's Sharpe ratio over the past 5 years was 0.74, against 0.79 for the S&P 500, so NTRA earned less for each unit of risk than an index fund did. The Sharpe ratio is the return earned above cash for each unit of volatility: two investments with the same return are not equal if one got there with far bigger swings. Guide: Balancing reward with risk (Sharpe ratio) →
- Worst decline
- NTRA's worst fall from a peak to a low over the past 10 years was 77.7%, against 33.7% for the S&P 500. Losses and gains are not symmetric: climbing back from a 77.7% fall takes a 349% gain. Guide: Market crash risk and tail risk →
- Correlation
- Over the past 5 years, NTRA's monthly returns had a correlation of 0.42 with the S&P 500. Correlation runs from 1 (moving in lockstep) through 0 (unrelated) to −1 (moving in opposite directions). They often move together: some diversification next to an index fund, but not a cushion. In the table, the correlation column measures each option against NTRA instead: the lower it is, the more that option would diversify a NTRA holding. Guide: Correlation and diversification →
Show all 125 stocks and funds worth at least $500 million that earned more than NTRA with less volatility
Out of 3,633 tested over 5 years. The strongest 100 are listed, best first, with funds that hold the same thing listed once.
| # | Investment | Found in | Annual return | Volatility | Sharpe | Worst decline | 10Y return | Corr. with NTRA | Expense |
|---|---|---|---|---|---|---|---|---|---|
| 1 | Whole market | +77.0% | 46.7% | 1.46 | −49.7% | +5,305% | 0.33 | — | |
| 2 | Whole market | +51.8% | 37.5% | 1.31 | −71.7% | +768% | -0.02 | — | |
| 3 | Whole market | +58.0% | 51.9% | 1.14 | −66.3% | +13,019% | 0.22 | — | |
| 4 | Whole market | +47.3% | 32.5% | 1.36 | −68.9% | +1,028% | 0.29 | — | |
| 5 | Whole market | +42.1% | 24.7% | 1.55 | −46.1% | +349% | 0.30 | — | |
| 6 | Whole market | +48.3% | 44.5% | 1.11 | −48.3% | +2,380% | 0.10 | — | |
| 7 | Whole market | +31.5% | 38.5% | 0.91 | −56.6% | +1,505% | 0.19 | — | |
| 8 | Whole market | +40.7% | 32.8% | 1.21 | −34.5% | +1,807% | 0.25 | — | |
| 9 | Whole market | +33.1% | 25.9% | 1.24 | −62.3% | +319% | -0.13 | — | |
| 10 | Whole market | +31.1% | 31.9% | 1.01 | −43.4% | +936% | 0.23 | — | |
| 11 | Whole market | +55.2% | 54.4% | 1.08 | −59.6% | +3,701% | 0.09 | — | |
| 12 | Whole market | +33.2% | 29.4% | 1.13 | −54.9% | +483% | 0.03 | — | |
| 13 | Whole market | +37.4% | 49.9% | 0.89 | −56.4% | +2,989% | 0.33 | — | |
| 14 | Whole market | +49.0% | 49.0% | 1.06 | −52.2% | +3,439% | 0.27 | — | |
| 15 | Whole market | +38.7% | 25.0% | 1.44 | −38.1% | +586% | 0.05 | — | |
| 16 | INSWInternational Seaways, Inc. · Oil & Gas | Whole market | +56.5% | 40.5% | 1.31 | −57.4% | — | 0.05 | — |
| 17 | Whole market | +31.9% | 43.4% | 0.86 | −48.0% | +1,274% | 0.29 | — | |
| 18 | Whole market | +33.8% | 32.2% | 1.07 | −37.5% | +965% | 0.47 | — | |
| 19 | Whole market | +57.4% | 48.7% | 1.18 | −57.0% | +2,698% | 0.24 | — | |
| 20 | Whole market | +38.7% | 46.7% | 0.94 | −46.3% | +2,534% | 0.29 | — | |
| 21 | Whole market | +38.7% | 33.3% | 1.16 | −69.6% | +542% | 0.19 | — | |
| 22 | Whole market | +44.2% | 36.9% | 1.18 | −71.9% | +1,061% | 0.02 | — | |
| 23 | Whole market | +35.4% | 35.4% | 1.04 | −55.1% | +935% | 0.31 | — | |
| 24 | Whole market | +53.7% | 53.5% | 1.07 | −70.5% | +911% | 0.19 | — | |
| 25 | Whole market | +33.6% | 30.6% | 1.10 | −45.7% | +345% | 0.12 | — | |
| 26 | Whole market | +32.0% | 40.7% | 0.89 | −55.3% | +1,017% | 0.00 | — | |
| 27 | Whole market | +33.2% | 32.9% | 1.04 | −64.2% | +430% | 0.13 | — | |
| 28 | Whole market | +33.7% | 29.4% | 1.14 | −47.6% | +474% | 0.15 | — | |
| 29 | Whole market | +48.8% | 43.0% | 1.15 | −52.5% | +967% | 0.32 | — | |
| 30 | Whole market | +39.3% | 37.2% | 1.08 | −45.5% | +2,045% | 0.29 | — | |
| 31 | Whole market | +31.4% | 42.1% | 0.86 | −51.5% | +616% | 0.19 | — | |
| 32 | Whole market | +53.4% | 48.6% | 1.13 | −53.3% | +1,195% | 0.32 | — | |
| 33 | Whole market | +33.4% | 36.9% | 0.97 | −45.3% | +1,665% | 0.33 | 0.35% | |
| 34 | Whole market | +32.9% | 42.2% | 0.89 | −56.9% | +483% | 0.22 | — | |
| 35 | Whole market | +45.2% | 52.6% | 0.97 | −49.5% | +1,600% | 0.19 | — | |
| 36 | ESLTElbit Systems Ltd. · Aerospace & Defense | Whole market | +39.8% | 34.6% | 1.15 | −35.4% | +765% | -0.09 | — |
| 37 | EMEEMCOR Group, Inc. · Engineering & Construction | Whole market | +43.0% | 35.3% | 1.20 | −48.0% | +1,202% | 0.30 | — |
| 38 | Whole market | +40.4% | 49.9% | 0.93 | −66.3% | +681% | -0.04 | — | |
| 39 | BAPCredicorp Ltd. · Banks | Whole market | +30.8% | 30.3% | 1.04 | −59.2% | +298% | 0.08 | — |
| 40 | STLDSteel Dynamics, Inc. · Metals & Mining | Whole market | +32.2% | 38.0% | 0.93 | −68.5% | +1,018% | 0.16 | — |
| 41 | JBLJabil Inc. · Electronics Manufacturing | Whole market | +35.8% | 39.6% | 0.97 | −57.3% | +1,264% | 0.13 | — |
| 42 | FLEXFlex Ltd. · Electronics Manufacturing | Whole market | +36.0% | 48.2% | 0.88 | −70.0% | +534% | 0.21 | — |
| 43 | GFIGold Fields Limited · Gold Mining | Whole market | +35.5% | 53.4% | 0.84 | −56.2% | +1,008% | -0.13 | — |
| 44 | SBSCompanhia de Saneamento Básico do Estado de São Paulo - SABESP · Water Utilities | Whole market | +39.1% | 37.1% | 1.08 | −62.0% | +293% | 0.07 | — |
| 45 | CIBGrupo Cibest S.A. · Banks | Whole market | +32.9% | 32.9% | 1.03 | −70.4% | +345% | 0.08 | — |
| 46 | NVTnVent Electric plc · Electrical Equipment | Whole market | +35.4% | 38.0% | 0.99 | −56.2% | — | 0.39 | — |
| 47 | KGCKinross Gold Corporation · Gold Mining | Whole market | +32.7% | 45.6% | 0.85 | −67.9% | +572% | 0.02 | — |
| 48 | CWCurtiss-Wright Corporation · Aerospace & Defense | Whole market | +30.8% | 28.7% | 1.08 | −48.7% | +512% | 0.20 | — |
| 49 | TSEMTower Semiconductor Ltd. · Semiconductors | Whole market | +42.5% | 52.2% | 0.93 | −62.3% | +1,058% | 0.27 | — |
| 50 | THCTenet Healthcare Corporation · Health Care Facilities | Whole market | +32.9% | 45.1% | 0.86 | −71.7% | +1,058% | 0.34 | — |
| 51 | COKECoca-Cola Consolidated, Inc. · Food & Beverages | Whole market | +41.2% | 38.0% | 1.10 | −51.7% | +1,569% | 0.19 | — |
| 52 | MLIMueller Industries, Inc. · Metal Fabrication | Whole market | +38.9% | 33.4% | 1.16 | −53.0% | +800% | 0.21 | — |
| 53 | MOG-AMoog Inc. · Aerospace & Defense | Whole market | +36.6% | 32.0% | 1.14 | −63.7% | +595% | 0.35 | — |
| 54 | FROFrontline Plc · Oil & Gas | Whole market | +52.6% | 49.7% | 1.10 | −52.0% | +1,194% | 0.08 | — |
| 55 | AGIAlamos Gold Inc. · Gold Mining | Whole market | +32.6% | 42.4% | 0.88 | −66.1% | +294% | 0.05 | — |
| 56 | TTMITTM Technologies, Inc. · Electronic Components | Whole market | +48.0% | 54.3% | 0.99 | −57.6% | +707% | 0.18 | — |
| 57 | Whole market | +51.2% | 33.4% | 1.41 | −79.7% | +1,387% | 0.08 | — | |
| 58 | IDCCInterDigital, Inc. · Intellectual Property Licensing | Whole market | +39.0% | 36.9% | 1.08 | −64.9% | +395% | 0.28 | — |
| 59 | JXNJackson Financial Inc. · Life Insurance | Whole market | +41.7% | 43.3% | 1.03 | −48.4% | — | 0.22 | — |
| 60 | SANMSanmina Corporation · Electronics Manufacturing | Whole market | +34.7% | 47.8% | 0.86 | −55.9% | +499% | 0.18 | — |
| 61 | LAURLaureate Education, Inc. · Education Services | Whole market | +37.5% | 32.8% | 1.14 | −64.5% | — | 0.19 | — |
| 62 | SNEXStoneX Group Inc. · Capital Markets | Whole market | +33.0% | 37.3% | 0.96 | −48.7% | +670% | 0.11 | — |
| 63 | AGXArgan, Inc. · Engineering & Construction | Whole market | +53.5% | 54.1% | 1.06 | −56.7% | +700% | 0.08 | — |
| 64 | TRMDTORM plc · Marine Shipping | Whole market | +54.3% | 45.9% | 1.18 | −60.6% | — | 0.07 | — |
| 65 | BWLPBW LPG Limited · Marine Shipping | Whole market | +60.3% | 50.9% | 1.19 | −68.8% | +2,672% | 0.02 | — |
| 66 | MIRMMirum Pharmaceuticals, Inc. · Biotechnology | Whole market | +40.0% | 51.8% | 0.91 | −63.8% | — | 0.24 | — |
| 67 | NHCNational HealthCare Corporation · Medical - Care Facilities | Whole market | +32.0% | 28.5% | 1.12 | −35.3% | +394% | 0.35 | — |
| 68 | TNKTeekay Tankers Ltd. · Marine Shipping | Whole market | +50.5% | 45.1% | 1.14 | −63.4% | +490% | 0.06 | — |
| 69 | GFFGriffon Corporation · Building Products | Whole market | +36.4% | 41.7% | 0.95 | −61.3% | +761% | 0.34 | — |
| 70 | DHTDHT Holdings, Inc. · Marine Shipping | Whole market | +38.7% | 39.0% | 1.04 | −39.7% | +1,050% | 0.08 | — |
| 71 | USLMUnited States Lime & Minerals, Inc. · Construction Materials | Whole market | +35.6% | 36.1% | 1.03 | −45.9% | +803% | 0.26 | — |
| 72 | LPGDorian LPG Ltd. · Oil & Gas Midstream | Whole market | +54.6% | 43.6% | 1.22 | −62.9% | +1,821% | -0.06 | — |
| 73 | BLXBladex, Inc. · Banks - Regional | Whole market | +31.4% | 25.9% | 1.19 | −68.5% | +290% | 0.33 | — |
| 74 | UFPTUFP Technologies, Inc. · Medical - Devices | Whole market | +35.8% | 46.0% | 0.90 | −48.3% | +1,006% | 0.33 | — |
| 75 | TENTsakos Energy Navigation Limited · Oil & Gas Midstream | Whole market | +46.9% | 46.3% | 1.07 | −68.7% | +211% | 0.02 | — |
| 76 | ATIATI Inc. · Metals & Mining | Whole market | +61.8% | 42.9% | 1.34 | −82.4% | +929% | 0.21 | — |
| 77 | PLPCPreformed Line Products Company · Electrical Equipment & Parts | Whole market | +40.5% | 48.3% | 0.94 | −59.5% | +827% | 0.20 | — |
| 78 | ESQEsquire Financial Holdings, Inc. · Banks - Regional | Whole market | +31.7% | 31.7% | 1.03 | −56.5% | — | 0.06 | — |
| 79 | CRSCarpenter Technology Corporation · Metals & Mining | Whole market | +63.9% | 46.5% | 1.30 | −74.7% | +1,021% | 0.22 | — |
| 80 | IGICInternational General Insurance Holdings Ltd. · Insurance - Diversified | Whole market | +30.8% | 30.9% | 1.03 | −50.6% | — | 0.04 | — |
| 81 | ODCOil-Dri Corporation of America · Chemicals - Specialty | Whole market | +35.9% | 36.9% | 1.02 | −48.9% | +460% | 0.16 | — |
| 82 | NWPXNWPX Infrastructure, Inc. · Construction Materials | Whole market | +32.5% | 36.2% | 0.96 | −46.5% | +682% | 0.29 | — |
| 83 | ASCArdmore Shipping Corporation · Marine Shipping | Whole market | +41.7% | 44.8% | 1.01 | −71.2% | +259% | -0.07 | — |
| 84 | Whole market | +36.0% | 31.0% | 1.15 | −80.9% | +139% | 0.35 | — | |
| 85 | CLMBClimb Global Solutions, Inc. · Technology Distributors | Whole market | +37.8% | 45.5% | 0.94 | −53.4% | +847% | 0.19 | — |
| 86 | Whole market | +50.3% | 37.5% | 1.28 | −75.3% | +674% | -0.07 | — | |
| 87 | Whole market | +31.7% | 33.9% | 0.99 | −73.8% | +332% | 0.10 | — | |
| 88 | BELFBBel Fuse Inc. · Hardware, Equipment & Parts | Whole market | +78.0% | 52.1% | 1.37 | −79.8% | +872% | 0.07 | — |
| 89 | Whole market | +33.1% | 32.5% | 1.05 | −73.5% | +295% | -0.04 | — | |
| 90 | Whole market | +41.8% | 31.7% | 1.27 | −90.8% | +829% | 0.17 | — | |
| 91 | Whole market | +34.3% | 32.0% | 1.09 | −77.1% | +430% | -0.05 | — | |
| 92 | FTITechnipFMC plc · Oilfield Services | Whole market | +54.1% | 41.3% | 1.26 | −85.8% | +178% | 0.03 | — |
| 93 | Whole market | +32.2% | 42.8% | 0.86 | −85.5% | −3.6% | 0.26 | — | |
| 94 | YPFYPF Sociedad Anónima · Integrated Oil & Gas | Whole market | +60.7% | 54.1% | 1.14 | −90.1% | +173% | 0.33 | — |
| 95 | DINOHF Sinclair Corporation · Oil & Gas | Whole market | +31.8% | 38.8% | 0.91 | −77.3% | +649% | 0.01 | — |
| 96 | UNMUnum Group · Life Insurance | Whole market | +30.6% | 29.3% | 1.06 | −81.0% | +256% | -0.01 | — |
| 97 | PRPermian Resources Corporation · Exploration & Production | Whole market | +33.1% | 47.1% | 0.85 | −98.9% | +99.2% | 0.15 | — |
| 98 | XPOXPO Logistics, Inc. · Freight & Logistics | Whole market | +30.5% | 47.0% | 0.80 | −64.5% | +1,467% | 0.24 | — |
| 99 | MTSIMACOM Technology Solutions Holdings, Inc. · Semiconductors | Whole market | +32.1% | 47.3% | 0.83 | −80.8% | +588% | 0.49 | — |
| 100 | EMBJEmbraer S.A. · Aerospace & Defense | Whole market | +32.8% | 45.0% | 0.86 | −85.2% | +283% | 0.42 | — |
NTRA against its popular alternatives
The investments people most often weigh against NTRA, compared period by period and year by year.
How do NTRA's risk and return compare with its alternatives?
This map plots each investment's annual return over the past 5 years against its volatility, the size of its typical price swings. Investments toward the upper left earned more for a smoother ride, and those toward the lower right earned less for a rougher one. The dashed lines cross at NTRA, which divides the map into what did better or worse on each measure.
- None of the 17 popular alternatives earned more than NTRA over the past 5 years with smaller price swings, so every higher return on the map came with a bumpier ride.
- Nine of the 17 popular alternatives earned less than NTRA over the past 5 years while swinging more, the weaker corner of the map.
- Over the past 5 years, NTRA returned 29.3% a year, more than the S&P 500's 12.7%, with higher volatility (57.6% against 17.1%).
Green points earned more than NTRA with less volatility; red points earned less with more. Hover over a point for its figures. Total returns with dividends reinvested, annualized.
All figures
| Investment | Annual return | Volatility |
|---|---|---|
| NTRA This pageNatera, Inc. | +29.3% | 57.6% |
| SPY S&P 500State Street SPDR S&P 500 ETF | +12.7% | 17.1% |
| DGX Quest Diagnostics Incorporated | +12.3% | 22.5% |
| GH Guardant Health, Inc. | +8.8% | 67.9% |
| LH Labcorp Holdings Inc. | +7.3% | 23.8% |
| TMO Thermo Fisher Scientific Inc. | +2.9% | 27.8% |
| BDX Becton, Dickinson and Company | +2.3% | 24.1% |
| QGEN Qiagen N.V. | +0.6% | 26.9% |
| VCYT Veracyte, Inc. | −0.7% | 64.8% |
| CDNA CareDx, Inc | −0.8% | 79.5% |
| DHR Danaher Corporation | −3.8% | 29.1% |
| PSNL Personalis, Inc. | −4.0% | 103% |
| ADPT Adaptive Biotechnologies Corporation | −6.4% | 78.7% |
| ILMN Illumina, Inc. | −7.8% | 46.9% |
| RGEN Repligen Corporation | −7.8% | 51.3% |
| TXG 10x Genomics, Inc. | −15.1% | 70.8% |
| NEO NeoGenomics, Inc. | −17.9% | 70.2% |
| MYGN Myriad Genetics, Inc. | −29.9% | 68.3% |
| PACB Pacific Biosciences of California, Inc. | −40.0% | 97.0% |
Has NTRA consistently beaten its popular alternatives?
This section compares NTRA with the investments people most often weigh against it, checking each one over eight periods from one month to ten years. Counting how often an alternative earned more than NTRA helps separate lasting outperformance from a single strong stretch.
- None of the 17 popular alternatives outperformed NTRA in at least 3 of 5 short-term and 2 of 3 long-term timeframes. The closest was CDNA.
A green cell means the alternative earned more than NTRA over that period. "Qualified" marks those that did so in at least 3 of 5 short-term periods and 2 of 3 long-term periods.
| Investment | Periods outperformed | Short term | Long term | Risk · 5 years | Fund | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Volatilitylower is calmer | Sharpehigher is better | Worst declinepast 10 years | Expense | Assets | Overlapsame sectors | ||
| NTRA Natera, Inc. (this page) | — | +9.5% | +54.6% | +95.4% | +77.4% | +115% | +896% | +261% | +3,841% | 57.6% | 0.74 | −77.7% | — | $59B | — |
| CDNA Medical - Diagnostics & ResearchCareDx, Inc | 5/5 short1/3 long | +27.4% | +80.3% | +225% | +262% | +355% | +1,203% | −3.8% | +1,634% | 79.5% | 0.39 | −94.9% | — | $3.6B | — |
| PSNL Medical - Diagnostics & ResearchPersonalis, Inc. | 2/5 short1/3 long | −1.8% | +19.5% | +151% | +103% | +57.5% | +1,582% | −18.7% | — | 103% | 0.45 | −98.2% | — | $1.7B | — |
| ILMN Medical - Diagnostics & ResearchIllumina, Inc. | 4/5 short0/3 long | +12.2% | +45.1% | +102% | +99.4% | +169% | +130% | −33.3% | +93.0% | 46.9% | 0.06 | −86.2% | — | $40B | — |
| TXG Biotechnology10x Genomics, Inc. | 4/5 short0/3 long | −9.7% | +65.3% | +191% | +330% | +444% | +81.2% | −55.8% | — | 70.8% | 0.12 | −96.5% | — | $9.3B | — |
| NEO Medical - Diagnostics & ResearchNeoGenomics, Inc. | 1/5 short0/3 long | −14.4% | +16.7% | +102% | +41.3% | +56.9% | +19.6% | −62.6% | +114% | 70.2% | 0.07 | −91.9% | — | $2.2B | — |
| MYGN Medical - Diagnostics & ResearchMyriad Genetics, Inc. | 1/5 short0/3 long | +38.2% | −6.4% | +7.8% | −9.8% | −29.9% | −63.2% | −83.0% | −71.7% | 68.3% | -0.16 | −94.3% | — | $530M | — |
| PACB Medical - DevicesPacific Biosciences of California, Inc. | 1/5 short0/3 long | +44.1% | +44.1% | +12.6% | +6.5% | −1.0% | −73.5% | −92.2% | −77.9% | 97.0% | -0.04 | −98.2% | — | $609M | — |
| GH Medical - Diagnostics & ResearchGuardant Health, Inc. | 1/5 short0/3 long | −6.5% | +9.8% | +78.5% | +59.8% | +132% | +534% | +52.8% | — | 67.9% | 0.46 | −91.0% | — | $22B | — |
| RGEN Medical - Instruments & SuppliesRepligen Corporation | 0/5 short0/3 long | −1.0% | +22.9% | +35.5% | +8.8% | +15.8% | +22.5% | −33.3% | +514% | 51.3% | 0.10 | −68.3% | — | $11B | — |
| VCYT Medical - Diagnostics & ResearchVeracyte, Inc. | 0/5 short0/3 long | +7.9% | −21.8% | +33.9% | +5.7% | +22.2% | +114% | −3.6% | +451% | 64.8% | 0.31 | −81.2% | — | $3.6B | — |
| TMO Medical - Diagnostics & ResearchThermo Fisher Scientific Inc. | 0/5 short0/3 long | +4.3% | +30.7% | +30.9% | +16.3% | +26.8% | +49.5% | +15.1% | +366% | 27.8% | 0.24 | −40.9% | — | $254B | — |
| DGX Medical - Diagnostics & ResearchQuest Diagnostics Incorporated | 0/5 short0/3 long | −2.9% | +14.5% | +21.6% | +38.6% | +26.5% | +103% | +78.5% | +243% | 22.5% | 0.63 | −36.6% | — | $26B | — |
| DHR Medical - Diagnostics & ResearchDanaher Corporation | 0/5 short0/3 long | +4.0% | +11.6% | +15.0% | −2.2% | +8.3% | +10.8% | −17.6% | +232% | 29.1% | 0.01 | −43.8% | — | $157B | — |
| LH Medical - Diagnostics & ResearchLabcorp Holdings Inc. | 0/5 short0/3 long | +0.7% | +15.0% | +20.6% | +29.3% | +12.2% | +67.4% | +42.4% | +184% | 23.8% | 0.42 | −46.6% | — | $26B | — |
| QGEN Medical - Diagnostics & ResearchQiagen N.V. | 0/5 short0/3 long | +9.2% | +20.8% | +20.2% | +8.7% | +6.3% | +45.9% | +3.0% | +111% | 26.9% | 0.15 | −41.4% | — | $10B | — |
| BDX Medical - Instruments & SuppliesBecton, Dickinson and Company | 0/5 short0/3 long | +7.2% | +26.2% | +23.7% | +28.9% | +32.3% | +1.6% | +12.2% | +71.4% | 24.1% | 0.22 | −39.9% | — | $53B | — |
| ADPT BiotechnologyAdaptive Biotechnologies Corporation | 0/5 short0/3 long | −12.3% | +11.7% | +67.5% | +53.5% | +37.0% | +493% | −28.0% | — | 78.7% | 0.30 | −96.5% | — | $3.9B | — |
How did NTRA do year by year?
This table shows each investment's total return in every full calendar year since 2016, along with where NTRA ranked among its popular alternatives each year. Annual results reveal how consistently each one kept pace with NTRA and how far its good and bad years diverged, detail that multiyear averages tend to smooth over.
Note: NTRA began trading on July 1, 2015, so the table starts with 2016, its first full calendar year, and cannot show how it fared during the dot-com bust, the 2008 financial crisis or two other sell-offs.
- NTRA finished ahead of the S&P 500 in six of its ten full calendar years, and ahead of it in each of the last three.
- Ranked against its popular alternatives each year, NTRA finished in the top quarter in six of ten years and in the bottom quarter in one. In 2025, it ranked 3 of 18.
- None of the 17 popular alternatives came out ahead of NTRA in most of the years they have in common.
Newest year first. Green marks a year in which the fund came out ahead of NTRA; gray means the two finished within a fraction of a point. The rank row places NTRA among the alternatives that traded the full year; dark green is the top quarter and red the bottom quarter.
| Investment | Years ahead of NTRA | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NTRA This pageNatera, Inc. | — | +44.7% | +153% | +55.9% | −57.0% | −6.2% | +195% | +141% | +55.3% | −23.2% | +8.4% |
| Rank among alternatives | Top quarter in 6 of 10 | 3 of 18 | 2 of 18 | 2 of 18 | 11 of 18 | 11 of 18 | 4 of 18 | 1 of 15 | 4 of 14 | 13 of 14 | 6 of 14 |
| SPY S&P 500State Street SPDR S&P 500 ETF | 4 of 10 | +17.7% | +24.9% | +26.2% | −18.2% | +28.7% | +18.3% | +31.2% | −4.6% | +21.7% | +12.0% |
| CDNA CareDx, Inc | 3 of 10 | −12.0% | +78.4% | +5.2% | −74.9% | −37.2% | +236% | −14.2% | +243% | +172% | −57.8% |
| PSNL Personalis, Inc. | 2 of 6 | +37.7% | +175% | +6.1% | −86.1% | −61.0% | +236% | — | — | — | — |
| ILMN Illumina, Inc. | 3 of 10 | −1.8% | −1.3% | −31.1% | −46.9% | +2.8% | +11.5% | +10.6% | +37.3% | +70.7% | −33.3% |
| TXG 10x Genomics, Inc. | 1 of 6 | +13.6% | −74.3% | +53.6% | −75.5% | +5.2% | +85.7% | — | — | — | — |
| NEO NeoGenomics, Inc. | 2 of 10 | −28.6% | +1.9% | +75.1% | −72.9% | −36.6% | +85.5% | +132% | +42.3% | +3.4% | +8.8% |
| MYGN Myriad Genetics, Inc. | 3 of 10 | −55.1% | −28.4% | +31.9% | −47.4% | +39.6% | −27.4% | −6.3% | −15.4% | +106% | −61.4% |
| PACB Pacific Biosciences of California, Inc. | 2 of 10 | +2.2% | −81.3% | +19.9% | −60.0% | −21.1% | +405% | −30.5% | +180% | −30.5% | −71.1% |
| GH Guardant Health, Inc. | 1 of 7 | +234% | +12.9% | −0.5% | −72.8% | −22.4% | +64.9% | +108% | — | — | — |
| RGEN Repligen Corporation | 4 of 10 | +13.8% | −20.0% | +6.2% | −36.1% | +38.2% | +107% | +75.4% | +45.4% | +17.7% | +8.9% |
| VCYT Veracyte, Inc. | 3 of 10 | +6.3% | +44.0% | +15.9% | −42.4% | −15.8% | +75.3% | +122% | +92.7% | −15.6% | +7.5% |
| TMO Thermo Fisher Scientific Inc. | 3 of 10 | +11.8% | −1.7% | −3.4% | −17.3% | +43.5% | +43.7% | +45.6% | +18.2% | +35.0% | −0.1% |
| DGX Quest Diagnostics Incorporated | 4 of 10 | +17.2% | +11.8% | −10.1% | −7.4% | +47.9% | +14.1% | +31.1% | −13.8% | +9.1% | +31.9% |
| DHR Danaher Corporation | 4 of 10 | +0.4% | −0.4% | −1.2% | −19.0% | +48.6% | +45.4% | +49.5% | +11.8% | +20.0% | +73.2% |
| LH Labcorp Holdings Inc. | 3 of 10 | +10.6% | +2.2% | +13.8% | −24.4% | +54.4% | +20.3% | +33.9% | −20.8% | +24.3% | +3.8% |
| QGEN Qiagen N.V. | 3 of 10 | +12.5% | +2.6% | −12.9% | −10.3% | +5.2% | +56.4% | −1.9% | +11.4% | +10.7% | +1.3% |
| BDX Becton, Dickinson and Company | 4 of 10 | −12.5% | −5.3% | −2.7% | +5.1% | +1.9% | −6.8% | +22.2% | +6.6% | +31.2% | +9.2% |
| ADPT Adaptive Biotechnologies Corporation | 1 of 6 | +171% | +22.4% | −35.9% | −72.8% | −52.5% | +97.6% | — | — | — | — |
Risk and diversification
How NTRA has fallen, how it held up in crashes beside the S&P 500 and its popular alternatives, and what moves independently of it.
What were NTRA's worst declines?
A drawdown is the decline from a peak to the lowest point before a new high. This section presents NTRA's five deepest drawdowns since it began trading in 2015, alongside the S&P 500's return over the same dates, and how long each took to recover. Together, these figures show how much an investor could have lost and how long it took to get back to even.
Note: NTRA began trading on July 1, 2015, so this list cannot include the dot-com bust, the 2008 financial crisis or two other sell-offs. The crash tests on this page show how older funds and the S&P 500 fared through those years.
- In all five of NTRA's worst declines, the S&P 500 held up better over the same dates.
- Not every decline was the market's doing: NTRA fell 30.8% from February to May 2021, while the S&P 500 rose 6.0%.
- The slowest recovery came after NTRA fell 70.0% from July 2015 to February 2016; it did not regain that peak until July 2018, two years later.
Green means NTRA fell less than the S&P 500 over the same dates. Based on daily closing prices with dividends reinvested.
| During | NTRA fell | S&P 500, same dates | Peak | Low | Time to the low | Back at the peak | Time to recover |
|---|---|---|---|---|---|---|---|
| 2022 bear market | −77.7% | −10.4% | Sep 2021 | May 2022 | 8 months | Sep 2024 | 2.3 years |
| 2015 China and oil sell-off | −70.0% | −9.3% | Jul 2015 | Feb 2016 | 7 months | Jul 2018 | 2.4 years |
| Late-2018 sell-off | −60.8% | −9.3% | Aug 2018 | Jan 2019 | 5 months | Aug 2019 | 7 months |
| Covid crash | −57.3% | −22.7% | Nov 2019 | Mar 2020 | 4 months | May 2020 | 2 months |
| No named crash | −30.8% | +6.0% | Feb 2021 | May 2021 | 3 months | Sep 2021 | 4 months |
How did NTRA do in stock market crashes?
This section measures how far NTRA, the S&P 500 and each alternative fell from peak to trough during every major market crash since 2000. A smaller decline means an investment held up better, and comparing results across crashes shows whether that resilience was consistent or a one-off.
Note: NTRA began trading on July 1, 2015, so its row reads "Not yet trading" for the dot-com bust, the 2008 financial crisis or two other sell-offs. The older alternatives and the S&P 500 show how those crashes played out.
- NTRA fell further than the S&P 500 in all six crashes it has traded through. The clearest case was the 2015 China and oil sell-off, when NTRA fell 61.5% and the S&P 500 fell 12.8%.
- Among its popular alternatives, MYGN held up best, falling less than NTRA in all six crashes they both traded through.
- NTRA began trading after the 2008 financial crisis, but ten of its popular alternatives lived through it. The mildest fall among them was DGX's 29.2%, against 55.2% for the S&P 500.
Newest crash first. Each figure is the fund's deepest fall within the crash window; green means a smaller fall than NTRA.
| Investment | Held up better | 2023 regional bank crisisMar 2023 | 2022 bear marketJan 2022 | Covid crashFeb 2020 | Late-2018 sell-offSep 2018 | February 2018 volatility shockFeb 2018 | 2015 China and oil sell-offAug 2015 | 2011 euro debt crisisJul 2011 | 2010 flash crashMay 2010 | 2008 financial crisisOct 2007 | Dot-com bustMar 2000 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NTRA This pageNatera, Inc. | — | −6.2% | −68.0% | −57.0% | −51.1% | −11.2% | −61.5% | Not yet trading | Not yet trading | Not yet trading | Not yet trading |
| SPY S&P 500State Street SPDR S&P 500 ETF | 6 of 6 | −3.4% | −24.5% | −33.7% | −19.3% | −6.5% | −12.8% | −17.9% | −1.5% | −55.2% | −47.5% |
| CDNA CareDx, Inc | 5 of 6 | −10.8% | −65.3% | −50.6% | −33.7% | −2.9% | −42.7% | — | — | — | — |
| PSNL Personalis, Inc. | 1 of 3 | −17.8% | −80.6% | −54.7% | — | — | — | — | — | — | — |
| ILMN Illumina, Inc. | 5 of 6 | −6.7% | −58.2% | −31.0% | −25.8% | −5.3% | −36.1% | −48.7% | −1.9% | −57.9% | — |
| TXG 10x Genomics, Inc. | 1 of 3 | −8.1% | −81.1% | −43.1% | — | — | — | — | — | — | — |
| NEO NeoGenomics, Inc. | 4 of 6 | −7.2% | −78.5% | −40.5% | −39.3% | −7.0% | −29.2% | −30.6% | −2.8% | −62.7% | — |
| MYGN Myriad Genetics, Inc. | 6 of 6 | −2.8% | −40.8% | −51.1% | −42.0% | −9.8% | −26.1% | −23.4% | −0.2% | −40.3% | −89.6% |
| PACB Pacific Biosciences of California, Inc. | 4 of 6 | −6.7% | −79.3% | −47.4% | −28.1% | −10.0% | −34.7% | −75.2% | — | — | — |
| GH Guardant Health, Inc. | 1 of 3 | −13.4% | −70.6% | −33.5% | — | — | — | — | — | — | — |
| RGEN Repligen Corporation | 6 of 6 | −4.9% | −38.7% | −22.2% | −29.9% | −8.6% | −44.4% | −17.1% | −3.7% | −51.9% | −90.7% |
| VCYT Veracyte, Inc. | 5 of 6 | −11.3% | −59.1% | −39.7% | −25.1% | −10.0% | −53.7% | — | — | — | — |
| TMO Thermo Fisher Scientific Inc. | 6 of 6 | −2.4% | −19.8% | −24.8% | −17.2% | −8.7% | −14.7% | −24.4% | −3.6% | −53.9% | −41.8% |
| DGX Quest Diagnostics Incorporated | 6 of 6 | −2.7% | −22.3% | −35.0% | −26.1% | −6.5% | −17.8% | −19.3% | −1.0% | −29.2% | −46.6% |
| DHR Danaher Corporation | 6 of 6 | −3.2% | −22.8% | −25.9% | −13.4% | −9.8% | −14.0% | −21.8% | −0.6% | −45.7% | −33.7% |
| LH Labcorp Holdings Inc. | 6 of 6 | −4.7% | −29.6% | −45.5% | −30.6% | −3.8% | −19.5% | −18.4% | −1.4% | −33.5% | −63.1% |
| QGEN Qiagen N.V. | 6 of 6 | −0.4% | −21.3% | −12.4% | −14.0% | −7.0% | −27.8% | −25.9% | −2.6% | −45.1% | −92.1% |
| BDX Becton, Dickinson and Company | 5 of 6 | −2.0% | −19.7% | −21.8% | −20.4% | −10.8% | −15.1% | −18.3% | −1.6% | −34.1% | — |
| ADPT Adaptive Biotechnologies Corporation | 1 of 3 | −10.0% | −75.8% | −50.3% | — | — | — | — | — | — | — |
How closely does NTRA move with the S&P 500?
Upside capture measures how much of the S&P 500's gains an investment kept in the months the market rose, and downside capture how much of its losses it took in the months the market fell. An investment that captures more of the gains than the losses has compounded ahead of the market over time. This section compares NTRA with its popular alternatives on both measures, and on beta (how strongly each has moved with the market), over the past 10 years.
- None of the 13 popular alternatives with the same record had a higher capture ratio (upside capture divided by downside capture) than NTRA's 2.06.
- Over the past 10 years, NTRA captured 169% of the S&P 500's gains in rising months and 82% of its losses in falling months, with a beta of 1.40. Its share of the market's gains was larger than its share of the losses.
Monthly total returns over the past 10 years, measured against SPY. 100% capture or a beta of 1.00 means moving in line with the S&P 500. Green marks a better figure than NTRA's: more upside, less downside or a higher capture ratio. Sorted by capture ratio.
| Investment | Upside capture | Downside capture | Capture ratio | Beta |
|---|---|---|---|---|
| NTRA This pageNatera, Inc. | 169% | 82% | 2.06 | 1.40 |
| DGX Quest Diagnostics Incorporated | 69% | 54% | 1.28 | 0.80 |
| CDNA CareDx, Inc | 186% | 161% | 1.16 | 1.56 |
| RGEN Repligen Corporation | 119% | 108% | 1.11 | 0.99 |
| DHR Danaher Corporation | 84% | 84% | 1.01 | 0.75 |
| VCYT Veracyte, Inc. | 128% | 128% | 1.00 | 1.41 |
| TMO Thermo Fisher Scientific Inc. | 104% | 104% | 1.00 | 0.81 |
| LH Labcorp Holdings Inc. | 81% | 91% | 0.89 | 0.97 |
| QGEN Qiagen N.V. | 62% | 83% | 0.75 | 0.45 |
| BDX Becton, Dickinson and Company | 53% | 77% | 0.69 | 0.48 |
| NEO NeoGenomics, Inc. | 116% | 169% | 0.68 | 1.26 |
| ILMN Illumina, Inc. | 120% | 200% | 0.60 | 1.19 |
| PACB Pacific Biosciences of California, Inc. | 76% | 234% | 0.33 | 1.70 |
| MYGN Myriad Genetics, Inc. | 68% | 233% | 0.29 | 1.63 |
What diversifies NTRA?
Correlation measures how closely two investments move together, on a scale from 1 (in lockstep) through 0 (unrelated) to -1 (in opposite directions). This section lists large ETFs and stocks whose returns have had a low correlation with NTRA's. Because such investments tend not to fall at the same time, pairing NTRA with them can reduce a portfolio's overall swings.
- Moving a fifth of the money in NTRA into GLD would have cut the portfolio's volatility by 20% over the past 5 years and raised its annual return (+30.0% for NTRA alone, +31.0% for the mix).
- MCK made money in three of the three calendar years in which NTRA lost money.
- Among large ETFs, LVHI, DXJ and EMLP have moved largely independently of NTRA over the past 5 years, with correlations of 0.17 or lower, and each still earned a positive 5-year return.
Only ETFs with at least $1.0B in assets and stocks worth at least $10B, with a correlation below 0.5 over the past 5 years and a positive return, are included, ranked by Sharpe ratio; funds that hold the same thing are shown once. The year columns are the years in which NTRA lost money. The last two columns show a portfolio that is 80% NTRA and 20% the other investment, rebalanced monthly.
ETFs
| Investment | Correlation | 5Y return | Sharpe | 2022 | 2021 | 2017 | 80/20 mix volatility | 80/20 mix annual return |
|---|---|---|---|---|---|---|---|---|
| NTRA Natera, Inc. (this page) | 1.00 | +261% | 0.74 | −57.0% | −6.2% | −23.2% | 55.5% | +30.0% |
| LVHI InternationalFranklin International Low Volatility High Dividend Index ETF | 0.11 | +119% | 1.48 | +3.8% | +17.8% | +10.0% | 44.6% | +30.3% |
| DXJ InternationalWisdomTree Japan Hedged Equity Fund | 0.17 | +225% | 1.34 | +6.0% | +18.0% | +22.8% | 44.9% | +32.4% |
| EMLP Broad MarketFirst Trust North American Energy Infrastructure Fund | 0.17 | +101% | 1.04 | +10.4% | +23.1% | +1.1% | 45.0% | +30.0% |
| HDV Dividend & IncomeiShares Core High Dividend ETF | 0.13 | +83.3% | 1.00 | +7.1% | +19.6% | +13.5% | 44.9% | +29.2% |
| SMH TechnologyVanEck Semiconductor ETF | 0.33 | +323% | 0.97 | −33.5% | +42.1% | +38.5% | 47.2% | +34.5% |
| DBEF InternationalXtrackers MSCI EAFE Hedged Equity ETF | 0.31 | +85.0% | 0.96 | −5.1% | +19.6% | +16.7% | 45.1% | +29.3% |
| GLD CommoditiesSPDR Gold Shares | -0.07 | +126% | 0.96 | −0.8% | −4.2% | +12.8% | 44.3% | +31.0% |
| SPMO Broad MarketInvesco S&P 500 Momentum ETF | 0.43 | +136% | 0.93 | −10.4% | +22.7% | +27.8% | 46.3% | +30.8% |
Stocks
| Investment | Correlation | 5Y return | Sharpe | 2022 | 2021 | 2017 | 80/20 mix volatility | 80/20 mix annual return |
|---|---|---|---|---|---|---|---|---|
| NTRA Natera, Inc. (this page) | 1.00 | +261% | 0.74 | −57.0% | −6.2% | −23.2% | 55.5% | +30.0% |
| CAH Medical - DistributionCardinal Health, Inc. | 0.30 | +479% | 1.55 | +54.1% | −0.4% | −12.7% | 46.3% | +34.6% |
| CLS Hardware, Equipment & PartsCelestica Inc. | 0.22 | +3,143% | 1.47 | +1.3% | +37.9% | −11.6% | 48.3% | +48.7% |
| FIX Engineering & ConstructionComfort Systems USA, Inc. | 0.33 | +1,636% | 1.46 | +17.0% | +89.0% | +32.1% | 48.1% | +43.8% |
| MCK Medical - DistributionMcKesson Corporation | 0.05 | +413% | 1.44 | +51.8% | +44.2% | +12.0% | 44.9% | +34.6% |
| MPC Oil & Gas Refining & MarketingMarathon Petroleum Corporation | 0.08 | +690% | 1.41 | +86.6% | +61.0% | +34.8% | 45.4% | +37.5% |
Common questions
What was NTRA's worst drawdown?
NTRA's deepest decline since it began trading in 2015 was 77.7%, from September 2021 to May 2022. It took 28 months from the low to climb back to its old high. Because NTRA launched in July 2015, that record does not include the dot-com bust, the 2008 financial crisis or two other sell-offs.
What were NTRA's best and worst years?
Over ten full calendar years, NTRA's best year was 2020, when it returned 195%. Its worst was 2022, with a return of -57.0%.
Is there a better investment than NTRA?
Across the whole market, 125 of the 3,633 stocks and funds worth at least $500 million earned more than NTRA with less volatility over the past 5 years, among them NVDA, TSM and AVGO.
Is NTRA more volatile than the S&P 500?
Yes. NTRA's volatility over the past 5 years was 57.6%, 3.4 times the S&P 500's 17.1%. Volatility measures how widely returns swing around their average: in roughly two years out of three, NTRA's return lands within 57.6% of its average, either way. The higher it is, the rougher the ride and the harder it is to hold through a slump.
What is NTRA's Sharpe ratio?
NTRA's Sharpe ratio over the past 5 years was 0.74, against 0.79 for the S&P 500, so NTRA earned less for each unit of risk than an index fund did. The Sharpe ratio is the return earned above cash for each unit of volatility: two investments with the same return are not equal if one got there with far bigger swings.
How correlated is NTRA with the S&P 500?
Over the past 5 years, NTRA's monthly returns had a correlation of 0.42 with the S&P 500. Correlation runs from 1 (moving in lockstep) through 0 (unrelated) to −1 (moving in opposite directions). They often move together: some diversification next to an index fund, but not a cushion. In the table, the correlation column measures each option against NTRA instead: the lower it is, the more that option would diversify a NTRA holding.
What are the best alternatives to NTRA?
None of the 17 popular alternatives we compared outperformed NTRA in at least 3 of 5 short-term and 2 of 3 long-term timeframes, which says more about NTRA's strength than about its alternatives.
Did NTRA outperform the S&P 500?
NTRA finished ahead of the S&P 500 (SPY) in six of ten full calendar years. In 2025, it returned +44.7%, against +17.7% for the index.
How did NTRA do in stock market crashes?
NTRA fell less than the S&P 500 (SPY) in none of the six major crashes it has traded through, and further in six. The clearest case was the 2015 China and oil sell-off, when NTRA fell 61.5% and the S&P 500 fell 12.8%.
What diversifies NTRA?
These had a low correlation with NTRA over the past 5 years and still earned a positive 5-year return: among large ETFs, LVHI (correlation 0.11), DXJ (correlation 0.17) and EMLP (correlation 0.17); among large stocks, CAH (correlation 0.30), CLS (correlation 0.22) and FIX (correlation 0.33). A correlation near zero means the two have moved largely independently.
How we measure
- Short-term periods are 1M, 3M, 6M, YTD, 1Y; long-term periods are 3Y, 5Y, 10Y. An investment outperformed in a period when its total return, with dividends reinvested, was higher than NTRA's. Returns within 0.5 points or 3% of NTRA's, whichever is larger, count as a tie.
- "Qualified" means outperforming in at least 3 of 5 short-term periods and 2 of 3 long-term periods. "All-weather" means outperforming in every long-term period and all but one short-term period.
- Popular alternatives are the funds and stocks most often compared with this one. We include only those that trade today, are not leveraged or inverse, and hold at least $200 million.
- Volatility is the annualized standard deviation of daily returns over 5 years, a measure of how much the price typically swings in a year. The Sharpe ratio is the return above cash for each unit of that volatility.
- A decline, or drawdown, runs from a peak to the lowest close before the next high. The worst decline ever uses all the price history we have; comparisons between funds use the past 10 years so that younger funds are judged on the same stretch.
- Sector overlap is the share of assets two funds hold in the same sectors. Correlation and the mixed-portfolio figures use monthly returns.
- Upside and downside capture follow Morningstar's definition: the compound monthly return in the months the S&P 500 rose (or fell), divided by the S&P 500's compound return in those months. Beta measures how strongly monthly returns have moved with the S&P 500. All three use the same window for every investment.
- Figures are computed from daily adjusted prices and update after each trading day. Past performance does not predict future results.